{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:45:44Z","timestamp":1788529544989,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12031-021-01964-x","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T23:02:22Z","timestamp":1643410942000},"page":"900-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson\u2019s Disease in Rats"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0137-3258","authenticated-orcid":false,"given":"Maria","family":"Lazarova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-3153","authenticated-orcid":false,"given":"Lyubka","family":"Tancheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2522-7020","authenticated-orcid":false,"given":"Radoslav","family":"Chayrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-5200","authenticated-orcid":false,"given":"Elina","family":"Tzvetanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7007-3665","authenticated-orcid":false,"given":"Albena","family":"Alexandrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1139-4960","authenticated-orcid":false,"given":"Andrey","family":"Popatanasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamara","family":"Uzunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-3890","authenticated-orcid":false,"given":"Miroslava","family":"Stefanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-5813","authenticated-orcid":false,"given":"Ivanka","family":"Stankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-3640","authenticated-orcid":false,"given":"Reni","family":"Kalfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"issue":"4","key":"1964_CR1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/brain\/awr028","volume":"134","author":"I Ahmed","year":"2011","unstructured":"Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G et al (2011) Glutamate NMDA receptor dysregulation in Parkinson\u2019s disease with dyskinesias. Brain 134(4):979\u2013986. https:\/\/doi.org\/10.1093\/brain\/awr028","journal-title":"Brain"},{"issue":"1","key":"1964_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF01244727","volume":"33","author":"IJ Bak","year":"1972","unstructured":"Bak IJ, Hassler R, Kim JS, Kataoka K (1972) Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioral changes. J Neural Transm 33(1):45\u201361. https:\/\/doi.org\/10.1007\/BF01244727","journal-title":"J Neural Transm"},{"issue":"4","key":"1964_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0028-3908(73)90087-7","volume":"12","author":"L Beani","year":"1973","unstructured":"Beani L, Bianchi C (1973) Effect of amantadine on cerebral acetyl-choline release and content in the guinea pig. Neuropharmacology 12(4):283\u2013289. https:\/\/doi.org\/10.1016\/0028-3908(73)90087-7","journal-title":"Neuropharmacology"},{"issue":"6","key":"1964_CR4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/j.1471-4159.2011.07376.x","volume":"118","author":"S Bido","year":"2011","unstructured":"Bido S, Marti M, Morari M (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J neurochem 118(6):1043\u20131055. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07376.x","journal-title":"J neurochem"},{"key":"1964_CR5","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/978-3-540-29678-2","volume-title":"Encyclopedia of Neuroscience","author":"M Binder","year":"2009","unstructured":"Binder M, Hirokawa N, Windhorst U (2009) Passive Avoidance Learning. In: Binder M, Hirokawa N, Windhorst U (eds) Encyclopedia of Neuroscience. Springer, Berlin, p 3093"},{"key":"1964_CR6","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.parkreldis.2008.04.015","volume":"14","author":"F Blandini","year":"2008","unstructured":"Blandini F, Armentero MT, Martignoni E (2008) The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14:S124\u2013S129. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.04.015","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1964_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1152\/jn.1997.77.1.309","volume":"77","author":"TA Blanpied","year":"1997","unstructured":"Blanpied TA, Boeckman FA, Aizenman E, Johnson JW (1997) Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 77(1):309\u2013323. https:\/\/doi.org\/10.1152\/jn.1997.77.1.309","journal-title":"J Neurophysiol"},{"issue":"13","key":"1964_CR8","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","volume":"25","author":"TA Blanpied","year":"2005","unstructured":"Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25(13):3312\u20133322. https:\/\/doi.org\/10.1523\/JNEUROSCI.4262-04.2005","journal-title":"J Neurosci"},{"issue":"1","key":"1964_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12640-016-9618-4","volume":"30","author":"M Bortolanza","year":"2016","unstructured":"Bortolanza M, Bariotto-dos-Santos KD, dos-Santos-Pereira M, da-Silva CA, Del-Bel E (2016) Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson\u2019s disease. Neurotox Res 30(1):88\u2013100. https:\/\/doi.org\/10.1007\/s12640-016-9618-4","journal-title":"Neurotox Res"},{"issue":"1","key":"1964_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 318(1):121\u2013134. https:\/\/doi.org\/10.1007\/s00441-004-0956-9","journal-title":"Cell Tissue Res"},{"issue":"8","key":"1964_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mds.20612","volume":"20","author":"JM Brotchie","year":"2005","unstructured":"Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20(8):919\u2013931. https:\/\/doi.org\/10.1002\/mds.20612","journal-title":"Mov Disord"},{"key":"1964_CR12","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1016\/j.parkreldis.2008.04.021","volume":"14","author":"M Carta","year":"2008","unstructured":"Carta M, Carlsson T, Mu\u00f1oz A, Kirik D, Bj\u00f6rklund A (2008a) Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat Disord 14:S154\u2013S158. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.04.021","journal-title":"Parkinsonism Relat Disord"},{"key":"1964_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","volume":"172","author":"M Carta","year":"2008","unstructured":"Carta M, Carlsson T, Mu\u00f1oz A, Kirik D, Bj\u00f6rklund A (2008b) Serotonin\u2013dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res 172:465\u2013478. https:\/\/doi.org\/10.1016\/S0079-6123(08)00922-9","journal-title":"Prog Brain Res"},{"issue":"1","key":"1964_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1096\/fj.00-0129com","volume":"15","author":"F Dabbeni-Sala","year":"2001","unstructured":"Dabbeni-Sala F, Santo S, Franceschini D, Skaper SD, Giusti P (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15(1):164\u2013170. https:\/\/doi.org\/10.1096\/fj.00-0129com","journal-title":"FASEB J"},{"issue":"4","key":"1964_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","volume":"21","author":"W Danysz","year":"1997","unstructured":"Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents\u2014preclinical studies. Neurosci Biobehav Rev 21(4):455\u2013468. https:\/\/doi.org\/10.1016\/S0149-7634(96)00037-1","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"1964_CR16","first-page":"342","volume":"57","author":"AW Dunah","year":"2000","unstructured":"Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG (2000) Alterations in subunit expression, composition, and phosphorylation of striataln-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson\u2019s disease. Mol Pharmacol 57(2):342\u2013352","journal-title":"Mol Pharmacol"},{"issue":"12","key":"1964_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","volume":"26","author":"S Duty","year":"2012","unstructured":"Duty S (2012) Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson\u2019s disease. CNS drugs 26(12):1017\u20131032. https:\/\/doi.org\/10.1007\/s40263-012-0016-z","journal-title":"CNS drugs"},{"issue":"2","key":"1964_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"GL Ellman","year":"1961","unstructured":"Ellman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7(2):88\u201395. https:\/\/doi.org\/10.1016\/0006-2952(61)90145-9","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1964_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1124\/mol.105.016667","volume":"69","author":"C Fiorentini","year":"2006","unstructured":"Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C (2006) Loss of synaptic D1 dopamine\/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol 69(3):805\u2013812","journal-title":"Mol Pharmacol"},{"issue":"11","key":"1964_CR20","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","volume":"26","author":"F Gardoni","year":"2006","unstructured":"Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G et al (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26(11):2914\u20132922. https:\/\/doi.org\/10.1523\/JNEUROSCI.5326-05.2006","journal-title":"J Neurosci"},{"issue":"3","key":"1964_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/026010618400300305","volume":"3","author":"AJ Gelenberg","year":"1984","unstructured":"Gelenberg AJ, Gibson CJ (1984) Tyrosine for the treatment of depression. Nutrition and health 3(3):163\u2013173. https:\/\/doi.org\/10.1177\/026010618400300305","journal-title":"Nutrition and health"},{"issue":"2","key":"1964_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12031-014-0284-9","volume":"54","author":"S Gheibi","year":"2014","unstructured":"Gheibi S, Aboutaleb N, Khaksari M, Kalalian-Moghaddam H, Vakili A, Asadi Y et al (2014) Hydrogen sulfide protects the brain against ischemic reperfusion injury in a transient model of focal cerebral ischemia. J Mol Neurosci 54(2):264\u2013270. https:\/\/doi.org\/10.1007\/s12031-014-0284-9","journal-title":"J Mol Neurosci"},{"issue":"2","key":"1964_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/cne.20323","volume":"479","author":"T Gonz\u00e1lez-Hern\u00e1ndez","year":"2004","unstructured":"Gonz\u00e1lez-Hern\u00e1ndez T, Barroso-Chinea P, de la Cruz Muros I, del Mar P\u00e9rez-Delgado M, Rodr\u00edguez M (2004) Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J Comp Neurol 479(2):198\u2013215. https:\/\/doi.org\/10.1002\/cne.20323","journal-title":"J Comp Neurol"},{"issue":"9","key":"1964_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","volume":"48","author":"JT Greenamyre","year":"1991","unstructured":"Greenamyre JT, O\u2019Brien CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson\u2019s disease. Arch Neurol 48(9):977\u2013981. https:\/\/doi.org\/10.1001\/archneur.1991.00530210109030","journal-title":"Arch Neurol"},{"issue":"10","key":"1964_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0024-3205(82)90596-3","volume":"30","author":"JH Growdon","year":"1982","unstructured":"Growdon JH, Melamed E, Logue M, Hefti F, Wurtman RJ (1982) Effects of oral L-tyrosine administration of CSF tyrosine and homovanillic acid levels in patients with Parkinson\u2019s disease. Life Sci 30(10):827\u2013832. https:\/\/doi.org\/10.1016\/0024-3205(82)90596-3","journal-title":"Life Sci"},{"issue":"1","key":"1964_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/pr.111.005678","volume":"65","author":"P Huot","year":"2013","unstructured":"Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease. Pharmacol Rev 65(1):171\u2013222","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1964_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2005.02.023","volume":"162","author":"R Iancu","year":"2005","unstructured":"Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson\u2019s disease in mice. Behav Brain Res 162(1):1\u201310. https:\/\/doi.org\/10.1016\/j.bbr.2005.02.023","journal-title":"Behav Brain Res"},{"issue":"S11","key":"1964_CR28","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord 20(S11):S11\u2013S16. https:\/\/doi.org\/10.1002\/mds.20458","journal-title":"Mov Disord"},{"issue":"1","key":"1964_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2466\/pr0.1967.21.1.221","volume":"21","author":"ME Jarvik","year":"1967","unstructured":"Jarvik ME, Kopp R (1967) An improved one-trial passive avoidance learning situation. Psychol Rep 21(1):221\u2013224. https:\/\/doi.org\/10.2466\/pr0.1967.21.1.221","journal-title":"Psychol Rep"},{"issue":"9","key":"1964_CR30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665\u2013677. https:\/\/doi.org\/10.1038\/nrn2471","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"1964_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bbr.2009.03.037","volume":"202","author":"A Kalda","year":"2009","unstructured":"Kalda A, Herm L, Rinken A, Zharkovsky A, Chen JF (2009) Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice. Behav Brain Res 202(2):232\u2013237. https:\/\/doi.org\/10.1016\/j.bbr.2009.03.037","journal-title":"Behav Brain Res"},{"issue":"2","key":"1964_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/mds.25273","volume":"28","author":"LV Kalia","year":"2013","unstructured":"Kalia LV, Brotchie JM, Fox SH (2013) Novel nondopaminergic targets for motor features of Parkinson\u2019s disease: review of recent trials. Mov Disord 28(2):131\u2013144. https:\/\/doi.org\/10.1002\/mds.25273","journal-title":"Mov Disord"},{"issue":"4","key":"1964_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","volume":"206","author":"J Kornhuber","year":"1991","unstructured":"Kornhuber J, Bormann J, H\u00fcbers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol: Molecular Pharmacology 206(4):297\u2013300. https:\/\/doi.org\/10.1016\/0922-4106(91)90113-V","journal-title":"Eur J Pharmacol: Molecular Pharmacology"},{"issue":"4","key":"1964_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12031-018-1171-6","volume":"66","author":"M Lazarova","year":"2018","unstructured":"Lazarova M, Popatanasov A, Klissurov R, Stoeva S, Pajpanova T, Kalfin R, Tancheva L (2018) Preventive effect of two new neurotensin analogues on Parkinson\u2019s disease rat model. J Mol Neurosci 66(4):552\u2013560. https:\/\/doi.org\/10.1007\/s12031-018-1171-6","journal-title":"J Mol Neurosci"},{"issue":"2","key":"1964_CR35","first-page":"43","volume":"309","author":"P Lemoine","year":"1989","unstructured":"Lemoine P, Robelin N, Sebert P, Mouret J (1989) L-tyrosine: a long term treatment of Parkinson\u2019s disease. C R Acad Sci III 309(2):43\u201347","journal-title":"C R Acad Sci III"},{"key":"1964_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fnagi.2017.00089","volume":"9","author":"DA Loeffler","year":"2017","unstructured":"Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA (2017) Increased oxidative stress markers in cerebrospinal fluid from healthy subjects with Parkinson\u2019s disease-associated LRRK2 gene mutations. Front Aging Neurosci 9:89\u201397. https:\/\/doi.org\/10.3389\/fnagi.2017.00089","journal-title":"Front Aging Neurosci"},{"key":"1964_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265\u2013275","journal-title":"J Biol Chem"},{"issue":"5","key":"1964_CR38","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","volume":"15","author":"E Luginger","year":"2000","unstructured":"Luginger E, Wenning GK, B\u00f6sch S, Poewe W (2000) Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 15(5):873\u2013878. https:\/\/doi.org\/10.1002\/1531-8257(200009)15:5%3c873::AID-MDS1017%3e3.0.CO;2-I","journal-title":"Mov Disord"},{"issue":"4\u20136","key":"1964_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0940-2993(98)80041-9","volume":"50","author":"A Lupp","year":"1998","unstructured":"Lupp A, Kerst S, Karge E, Quack G, Klinger W (1998) Investigation on possible antioxidative properties of the NMDA-receptor antagonists ketamine, memantine, and amantadine in comparison to nicanartine in vitro. Exp Toxicol Pathol 50(4\u20136):501\u2013506. https:\/\/doi.org\/10.1016\/S0940-2993(98)80041-9","journal-title":"Exp Toxicol Pathol"},{"issue":"2","key":"1964_CR40","first-page":"717","volume":"263","author":"A Lupp","year":"1992","unstructured":"Lupp A, L\u00fccking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263(2):717\u2013724","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1964_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/0003-9993(93)90072-I","volume":"74","author":"GJ Macchio","year":"1993","unstructured":"Macchio GJ, Ito V, Sahgal V (1993) Amantadine-induced coma. Arch Phys Med Rehabil 74(10):1119\u20131120. https:\/\/doi.org\/10.1016\/0003-9993(93)90072-I","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"1964_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2217\/nmt.13.77","volume":"4","author":"Z Majl\u00e1th","year":"2014","unstructured":"Majl\u00e1th Z, V\u00e9csei L (2014) NMDA antagonists as Parkinson\u2019s disease therapy: disseminating the evidence. Neurodegener Dis Manag 4(1):23\u201330. https:\/\/doi.org\/10.2217\/nmt.13.77","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"1964_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1385\/JMN\/31:02:127","volume":"31","author":"M Marvanova","year":"2007","unstructured":"Marvanova M, Nichols CD (2007) Identification of neuroprotective compounds of Caenorhabditis elegans dopaminergic neurons against 6-OHDA. J Mol Neurosci 31(2):127\u2013137. https:\/\/doi.org\/10.1385\/JMN\/31:02:127","journal-title":"J Mol Neurosci"},{"issue":"2","key":"1964_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0006-8993(74)90685-4","volume":"80","author":"PL McGeer","year":"1974","unstructured":"McGeer PL, Grewaal DS, McGeer EG (1974) Influence of noncholinergic drugs on rat striatal acetylcholine levels. Brain Res 80(2):211\u2013217. https:\/\/doi.org\/10.1016\/0006-8993(74)90685-4","journal-title":"Brain Res"},{"issue":"5","key":"1964_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nrd3430","volume":"10","author":"WG Meissner","year":"2011","unstructured":"Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P et al (2011) Priorities in Parkinson\u2019s disease research. Nat Rev Drug Discov 10(5):377\u2013393. https:\/\/doi.org\/10.1038\/nrd3430","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1964_CR46","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","volume":"56","author":"LV Metman","year":"1999","unstructured":"Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56(11):1383\u20131386. https:\/\/doi.org\/10.1001\/archneur.56.11.1383","journal-title":"Arch Neurol"},{"key":"1964_CR47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fneur.2014.00144","volume":"5","author":"N Morin","year":"2014","unstructured":"Morin N, Di Paolo T (2014) Pharmacological treatments inhibiting levodopa-induced dyskinesias in MPTP-lesioned monkeys: brain glutamate biochemical correlates. Front Neurol 5:144\u2013152. https:\/\/doi.org\/10.3389\/fneur.2014.00144","journal-title":"Front Neurol"},{"issue":"5","key":"1964_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/ana.410150503","volume":"15","author":"I Nakano","year":"1984","unstructured":"Nakano I, Hirano A (1984) Parkinson\u2019s disease: neuron loss in the nucleus basalis without concomitant Alzheimer\u2019s disease. Ann Neurol 15(5):415\u2013418. https:\/\/doi.org\/10.1002\/ana.410150503","journal-title":"Ann Neurol"},{"issue":"2","key":"1964_CR49","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S1734-1140(10)70264-4","volume":"62","author":"AM Nayebi","year":"2010","unstructured":"Nayebi AM, Rad SR, Saberian M, Azimzadeh S, Samini M (2010) Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT 1A receptors in rats. Pharmacol Rep 62(2):258\u2013264. https:\/\/doi.org\/10.1016\/S1734-1140(10)70264-4","journal-title":"Pharmacol Rep"},{"issue":"1","key":"1964_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev.neuro.23.1.185","volume":"23","author":"SM Nicola","year":"2000","unstructured":"Nicola SM, Surmeier DJ, Malenka RC (2000) Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 23(1):185\u2013215. https:\/\/doi.org\/10.1146\/annurev.neuro.23.1.185","journal-title":"Annu Rev Neurosci"},{"issue":"3","key":"1964_CR51","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.neuroscience.2009.01.034","volume":"159","author":"FE Padovan-Neto","year":"2009","unstructured":"Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA (2009) Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson\u2019s disease. Neuroscience 159(3):927\u2013935. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.01.034","journal-title":"Neuroscience"},{"issue":"10","key":"1964_CR52","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/0028-3908(95)00092-K","volume":"34","author":"CG Parsons","year":"1995","unstructured":"Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W et al (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34(10):1239\u20131258. https:\/\/doi.org\/10.1016\/0028-3908(95)00092-K","journal-title":"Neuropharmacology"},{"key":"1964_CR53","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"2006","unstructured":"Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates. Elsevier, New York"},{"issue":"5","key":"1964_CR54","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/jnnp.48.5.413","volume":"48","author":"EK Perry","year":"1985","unstructured":"Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA et al (1985) Cholinergic correlates of cognitive impairment in Parkinson\u2019s disease: comparisons with Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 48(5):413\u2013421. https:\/\/doi.org\/10.1136\/jnnp.48.5.413","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1964_CR55","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1590\/1516-4446-2017-2393","volume":"40","author":"IF Raupp-Barcaro","year":"2018","unstructured":"Raupp-Barcaro IF, Vital MA, Galdur\u00f3z JC, Andreatini R (2018) Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. Braz J Psychiatry 40(4):449\u2013458. https:\/\/doi.org\/10.1590\/1516-4446-2017-2393","journal-title":"Braz J Psychiatry"},{"issue":"5\u20136","key":"1964_CR56","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.brainresbull.2010.06.004","volume":"82","author":"M Roghani","year":"2010","unstructured":"Roghani M, Niknam A, Jalali-Nadoushan MR, Kiasalari Z, Khalili M, Baluchnejadmojarad T (2010) Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull 82(5\u20136):279\u2013283. https:\/\/doi.org\/10.1016\/j.brainresbull.2010.06.004","journal-title":"Brain Res Bull"},{"issue":"1","key":"1964_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1385-299X(97)00034-2","volume":"2","author":"G Rozas","year":"1997","unstructured":"Rozas G, Guerra MJ, Labandeira-Garc\u0131a JL (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Protoc 2(1):75\u201384. https:\/\/doi.org\/10.1016\/S1385-299X(97)00034-2","journal-title":"Brain Res Protoc"},{"issue":"1","key":"1964_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1124\/jpet.108.150425","volume":"330","author":"D Rylander","year":"2009","unstructured":"Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330(1):227\u2013235","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1964_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0006-2952(75)90304-4","volume":"24","author":"C Sachs","year":"1975","unstructured":"Sachs C, Jonsson G (1975) Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 24(1):1\u20138. https:\/\/doi.org\/10.1016\/0006-2952(75)90304-4","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1964_CR60","first-page":"689","volume":"18","author":"RK Schwarting","year":"1997","unstructured":"Schwarting RK, Huston JP (1997) Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. Neurotoxicology 18(3):689\u2013708","journal-title":"Neurotoxicology"},{"issue":"6","key":"1964_CR61","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/00002826-198712000-00003","volume":"10","author":"KM Shannon","year":"1987","unstructured":"Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL (1987) Amantadine and motor fluctuations in chronic Parkinson\u2019s disease. Clin Neuropharmacol 10(6):522\u2013526","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"1964_CR62","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0006-8993(87)90885-7","volume":"426","author":"RM Shapiro","year":"1987","unstructured":"Shapiro RM, Glick SD, Camarota NA (1987) A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res 426(2):323\u2013331. https:\/\/doi.org\/10.1016\/0006-8993(87)90885-7","journal-title":"Brain Res"},{"issue":"3\u20134","key":"1964_CR63","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03033565","volume":"11","author":"N Simola","year":"2007","unstructured":"Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson\u2019s disease. Neurotox Res 11(3\u20134):151\u2013167. https:\/\/doi.org\/10.1007\/BF03033565","journal-title":"Neurotox Res"},{"key":"1964_CR64","doi-asserted-by":"publisher","unstructured":"Stankova I, Lazarova M, Chayrov R, Popatanasov A, Tancheva L, Kalfin R (2021) Newly synthesized amantadine derivative: safety and neuropharmacological activity. Farmacia 69(6):1112\u20131119. https:\/\/doi.org\/10.31925\/farmacia.2021.6.14","DOI":"10.31925\/farmacia.2021.6.14"},{"issue":"1","key":"1964_CR65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/jnnp.2004.036558","volume":"75","author":"A Thomas","year":"2004","unstructured":"Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 75(1):141\u2013143","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1964_CR66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jnc.13696","volume":"139","author":"D Toulorge","year":"2016","unstructured":"Toulorge D, Schapira AH, Hajj R (2016) Molecular changes in the postmortem parkinsonian brain. J Neurochem 139:27\u201358. https:\/\/doi.org\/10.1111\/jnc.13696","journal-title":"J Neurochem"},{"issue":"6","key":"1964_CR67","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/ajcn\/64.6.916","volume":"64","author":"FJ van Spronsen","year":"1996","unstructured":"van Spronsen FJ, van Dijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, Heymans HS (1996) Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr 64(6):916\u2013921. https:\/\/doi.org\/10.1093\/ajcn\/64.6.916","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"1964_CR68","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/mds.23034","volume":"25","author":"E Wolf","year":"2010","unstructured":"Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P et al (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson\u2019s disease. Mov Disord 25(10):1357\u20131363. https:\/\/doi.org\/10.1002\/mds.23034","journal-title":"Mov Disord"},{"issue":"1","key":"1964_CR69","first-page":"146","volume":"21","author":"DR Wood","year":"1985","unstructured":"Wood DR, Reimherr FW, Wender PH (1985) Amino acid precursors for the treatment of attention deficit disorder, residual type. Psychopharmacol Bull 21(1):146\u2013149","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"1964_CR70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.410260106","volume":"26","author":"RM Zweig","year":"1989","unstructured":"Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL (1989) The pedunculopontine nucleus in Parkinson\u2019s disease. Ann Neurol 26(1):41\u201346. https:\/\/doi.org\/10.1002\/ana.410260106","journal-title":"Ann Neurol"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-021-01964-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12031-021-01964-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-021-01964-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T10:49:52Z","timestamp":1649242192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12031-021-01964-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1964"],"URL":"https:\/\/doi.org\/10.1007\/s12031-021-01964-x","relation":{},"ISSN":["0895-8696","1559-1166"],"issn-type":[{"value":"0895-8696","type":"print"},{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiments have been performed strictly according to the national regulations and European Communities Council Directive (86\/609\/EEC) also \u201cPrinciples of laboratory animal care\u201d (NIH publication No. 85-23) concerning the protection of animals used for scientific and experimental purposes. All efforts and study design was made with purpose to minimize number of the animals and their suffering.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare their consent for publication","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}